Plain-English translation of NCT06496789 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two treatments for locally advanced stomach cancer: chemotherapy (the standard cancer drug treatment) plus serplulimab, a newer type of immunotherapy drug that helps your immune system fight cancer. You would receive both treatments together before surgery to remove the tumor, and researchers want to see if this combination is effective and safe.
Stomach cancer that has grown deeper into the stomach wall or spread to nearby lymph nodes is difficult to treat. Doctors hope that combining traditional chemotherapy with this immunotherapy medication before surgery might help shrink tumors more effectively and improve survival chances for patients.
You would receive several cycles of chemotherapy combined with the new immunotherapy medication before your scheduled surgery. This involves regular clinic visits for drug infusions, blood tests, and imaging scans to monitor your tumor and how your body is responding. After completing the medication cycles, you would have surgery to remove the tumor. The trial aims to enroll 35 patients total and is currently recruiting participants at Tianjin Medical University Cancer Institute and Hospital.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Enrollment target
~35 participants
Started
May 2023
Primary completion
December 2024
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
hongjie zhan
Tianjin Medical University Cancer Institute and Hospital